Form 8-K - Current report:
SEC Accession No. 0001558370-25-006482
Filing Date
2025-05-06
Accepted
2025-05-06 16:01:12
Documents
15
Period of Report
2025-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vygr-20250506x8k.htm   iXBRL 8-K 40836
2 EX-99.1 vygr-20250506xex99d1.htm EX-99.1 121466
3 GRAPHIC vygr-20250506xex99d1001.jpg GRAPHIC 7635
  Complete submission text file 0001558370-25-006482.txt   303985

Data Files

Seq Description Document Type Size
4 EX-101.SCH vygr-20250506.xsd EX-101.SCH 3301
5 EX-101.LAB vygr-20250506_lab.xml EX-101.LAB 15267
6 EX-101.PRE vygr-20250506_pre.xml EX-101.PRE 9842
17 EXTRACTED XBRL INSTANCE DOCUMENT vygr-20250506x8k_htm.xml XML 4617
Mailing Address 75 HAYDEN AVENUE LEXINGTON MA 02421
Business Address 75 HAYDEN AVENUE LEXINGTON MA 02421 857-259-5340
Voyager Therapeutics, Inc. (Filer) CIK: 0001640266 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37625 | Film No.: 25917074
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)